Japan records surprise trade deficit in July as exports weaken further
Harrison Robert Gardner, the Chief Information Officer of Sera Prognostics , Inc. (NASDAQ:SERA), recently executed a series of stock transactions, according to a filing with the Securities and Exchange Commission. The company, currently valued at $146 million, maintains a FAIR financial health score according to InvestingPro analysis. On March 6, Gardner sold 3,251 shares of the company’s Class A Common Stock, generating proceeds of approximately $13,524. The shares were sold at a weighted average price of $4.16, with individual transactions ranging from $4.07 to $4.24. The stock, which has declined nearly 47% year-to-date, currently trades at $4.32.
On the previous day, Gardner acquired 25,770 shares of Class A Common Stock at no cost, as part of a restricted stock unit (RSU) grant. Additionally, on March 5, he received 36,830 stock options, exercisable at $4.20 per share, which will vest over a four-year period.
The sale of shares was conducted to cover tax withholding obligations arising from the vesting of RSUs, as mandated by Sera Prognostics’ policy. Following these transactions, Gardner holds a total of 125,631 shares of the company’s stock.
In other recent news, Sera Prognostics has announced several key developments. The company has launched a public offering of its Class A common stock and pre-funded warrants, with proceeds intended to expand U.S. operations, prepare for EU growth, and support FDA approval efforts for its PreTRM test. This offering is managed by Jefferies, TD Cowen, William Blair, and RBC Capital Markets, contingent on market conditions. Meanwhile, Sera Prognostics has also terminated a previous $50 million "at-the-market" stock offering, as indicated in a recent SEC filing, though the sales agreement with TD Cowen remains effective.
Additionally, the Society for Maternal Fetal Medicine has published an abstract with topline results from Sera Prognostics’ PRIME study, focusing on prematurity risk assessment and neonatal outcomes. Detailed findings from the study will be presented later this month at the SMFM 2025 Pregnancy Meeting. Following this presentation, the company plans a conference call and live audio webcast to discuss the results further. These updates reflect Sera Prognostics’ ongoing efforts in research and its strategies for capital raising to enhance its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.